All news

Fresenius raises 2026 outlook for second time as FMC cuts its own

Reuters via Global Banking & Finance · · AI-summarised by FinFlash

Fresenius lifted its full-year 2026 expectations after a stronger than anticipated third quarter led by its Kabi and Helios units. It now sees constant-currency core EPS growth at the upper end of its 10%-15% range and an EBIT margin above 11.5%, against about 11.5% before. It is the second upgrade this year after August. Fresenius Medical Care, 25% owned, cut its operating income outlook after a third straight quarterly fall in US treatment volumes.

So What?

Supportive for German healthcare names, with Fresenius up 4.31% in early Frankfurt trade. FMC's falling US volumes are the risk to watch for the wider dialysis group.

Read original source

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.